Imiglucerase replaces the deficiency of this enzyme, ceases to initial pathophysiological changes and prevents secondary pathological manifestations of disease.
GLURAZYME® treatment reduces size of spleen and liver, normalizes blood platelet counts, mineral bone density, reduces bone-marrow infiltration, weakening pain in the bones.
Glurazyme (imiglucerase) is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant non-neurological manifestations of the disease.
The non-neurological manifestations of Gaucher disease include one or more of the following conditions:
- bone disease
- hepatomegaly or splenomegaly
«GENERIUM» is the only one company in Russia that carried out the development and production of Imiglucerase biosimilar.